Total Payments
$90,557
2024 Payments
$1,840
Companies
82
Transactions
1,151
Medicare Patients
4,448
Medicare Billing
$618,514
Payment Breakdown by Category
Other$53,118 (58.7%)
Food & Beverage$21,175 (23.4%)
Consulting$10,584 (11.7%)
Travel$5,574 (6.2%)
Education$106.43 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,038 | 52 | 50.8% |
| Food and Beverage | $21,175 | 1,006 | 23.4% |
| Consulting Fee | $10,584 | 7 | 11.7% |
| Honoraria | $7,080 | 4 | 7.8% |
| Travel and Lodging | $5,574 | 74 | 6.2% |
| Education | $106.43 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Indivior Inc. | $35,451 | 169 | $0 (2024) |
| Alkermes, Inc. | $30,638 | 77 | $0 (2024) |
| BioDelivery Sciences International, Inc. | $6,021 | 21 | $0 (2021) |
| Collegium Pharmaceutical, Inc. | $3,855 | 72 | $0 (2024) |
| ABBVIE INC. | $1,725 | 101 | $0 (2024) |
| Novo Nordisk Inc | $1,089 | 63 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,027 | 53 | $0 (2024) |
| PFIZER INC. | $946.97 | 52 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $815.90 | 44 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $709.84 | 35 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,840 | 91 | ABBVIE INC. ($295.27) |
| 2023 | $4,554 | 101 | Alkermes, Inc. ($2,406) |
| 2022 | $4,998 | 100 | Alkermes, Inc. ($3,175) |
| 2021 | $7,955 | 134 | Alkermes, Inc. ($5,757) |
| 2020 | $10,239 | 112 | Indivior Inc. ($4,430) |
| 2019 | $12,328 | 163 | BioDelivery Sciences International, Inc. ($5,897) |
| 2018 | $31,702 | 270 | Indivior Inc. ($22,527) |
| 2017 | $16,942 | 180 | Alkermes, Inc. ($7,629) |
All Payment Transactions
1,151 individual payment records from CMS Open Payments — Page 1 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $24.78 | General |
| Category: Opioid Analgesic | ||||||
| 12/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: Obesity | ||||||
| 12/06/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: Diabetes | ||||||
| 12/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.20 | General |
| Category: NEUROSCIENCE | ||||||
| 11/27/2024 | Verity Pharmaceuticals Inc. | Tlando (Drug) | Food and Beverage | Cash or cash equivalent | $23.12 | General |
| Category: Testosterone Replacement Therapy (TRT) | ||||||
| 11/18/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $29.07 | General |
| Category: PAIN | ||||||
| 11/09/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Insomnia | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.96 | General |
| 11/07/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $7.81 | General |
| Category: Diabetes | ||||||
| 11/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: DIABETES | ||||||
| 10/18/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: SCHIZOPHRENIA | ||||||
| 10/16/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $19.59 | General |
| Category: Opioid Analgesic | ||||||
| 10/10/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $31.48 | General |
| Category: Opioid Use Disorder | ||||||
| 10/07/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/30/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/23/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: Diabetes | ||||||
| 09/19/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $20.11 | General |
| 09/13/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: Respiratory | ||||||
| 09/12/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/11/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: PAIN | ||||||
| 08/29/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: PSYCHIATRY | ||||||
| 08/29/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: Diabetes | ||||||
| 08/28/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,331 | 2,638 | $556,660 | $208,158 |
| 2022 | 12 | 1,200 | 2,214 | $441,985 | $164,102 |
| 2021 | 13 | 1,006 | 1,884 | $359,495 | $132,084 |
| 2020 | 13 | 911 | 1,708 | $354,475 | $114,170 |
Total Patients
4,448
Total Services
8,444
Medicare Billing
$618,514
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 245 | 919 | $298,675 | $100,172 | 33.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 223 | 342 | $94,050 | $27,057 | 28.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 128 | 128 | $35,200 | $20,033 | 56.9% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 145 | 151 | $24,160 | $13,864 | 57.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 51 | 56 | $25,200 | $8,911 | 35.4% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 164 | 661 | $26,440 | $8,163 | 30.9% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 105 | 105 | $13,300 | $7,954 | 59.8% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 21 | 21 | $7,350 | $5,926 | 80.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 124 | 125 | $5,000 | $4,643 | 92.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $14,260 | $4,528 | 31.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $5,500 | $2,107 | 38.3% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2023 | 14 | 14 | $2,540 | $1,831 | 72.1% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 35 | 35 | $1,400 | $1,300 | 92.9% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 15 | 20 | $2,400 | $1,032 | 43.0% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 19 | 19 | $1,185 | $636.31 | 53.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 225 | 560 | $175,075 | $63,218 | 36.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 253 | 614 | $156,500 | $43,875 | 28.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 113 | 113 | $28,275 | $17,707 | 62.6% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 131 | 136 | $20,320 | $12,893 | 63.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 45 | 57 | $24,825 | $9,531 | 38.4% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 180 | 474 | $18,960 | $5,874 | 31.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 69 | 69 | $6,900 | $4,847 | 70.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 104 | 106 | $4,040 | $3,823 | 94.6% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 14 | 19 | $2,280 | $861.11 | 37.8% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2022 | 33 | 33 | $1,485 | $662.31 | 44.6% |
About Dr. Daniel Glatt, MD
Dr. Daniel Glatt, MD is a Internal Medicine healthcare provider based in Burlingame, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649228917.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Glatt, MD has received a total of $90,557 in payments from pharmaceutical and medical device companies, with $1,840 received in 2024. These payments were reported across 1,151 transactions from 82 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($46,038).
As a Medicare-enrolled provider, Glatt has provided services to 4,448 Medicare beneficiaries, totaling 8,444 services with total Medicare billing of $618,514. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Addiction Medicine
- Location Burlingame, CA
- Active Since 05/05/2006
- Last Updated 03/13/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1649228917
Products in Payments
- SUBLOCADE (Drug) $28,186
- VIVITROL (Drug) $9,836
- Vivitrol 380 mg (Drug) $8,058
- Vivitrol (Drug) $6,585
- BELBUCA (Drug) $5,948
- SUBOXONE SUBLINGUAL FILM (Drug) $4,235
- Xtampza ER (Drug) $2,883
- VRAYLAR (Drug) $712.14
- XTAMPZA (Drug) $614.37
- LATUDA (Drug) $569.17
- JARDIANCE (Drug) $528.67
- STIOLTO RESPIMAT (Drug) $402.07
- XIFAXAN (Drug) $361.23
- NURTEC ODT (Drug) $354.44
- Ozempic (Drug) $345.11
- QULIPTA (Drug) $342.65
- REXULTI (Drug) $283.10
- CHANTIX (Drug) $257.57
- FARXIGA (Drug) $256.49
- UBRELVY (Drug) $251.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Burlingame
Dr. David Klonoff, M.d, M.D
Internal Medicine — Payments: $199,028
Internal Medicine $199,028
Dr. Simon Lee, M.d, M.D
Internal Medicine — Payments: $31,276
Internal Medicine $31,276
Dr. Ajanta De, M.d, M.D
Internal Medicine — Payments: $25,662
Internal Medicine $25,662
Andrew Glatt, M.d, M.D
Internal Medicine — Payments: $15,109
Internal Medicine $15,109
Ms. Nani Kanen
Internal Medicine — Payments: $13,532
Internal Medicine $13,532
Dr. Mahazarin Ginwalla, M.d, M.D
Internal Medicine — Payments: $12,707
Internal Medicine $12,707